{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007348","form_type":"8-K","ticker":"AZTA","cik":"0000933974","company_name":"Azenta, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.547281+00:00","generated_at":"2026-06-02T15:13:32.017569+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Azenta Q2 revenue $159M (+7%); non-GAAP EPS $0.05; $111M goodwill impairment; guides FY rev lower","bullets":["Revenue $159M, up 7% YoY; organic growth 7%; B Medical revenue up 51% to $23M.","GAAP diluted EPS from continuing ops ($2.47) vs ($0.03); includes $111.3M non-cash goodwill impairment in B Medical.","Non-GAAP diluted EPS $0.05 vs ($0.06); adjusted EBITDA $9M vs ($2M); margin 5.9% up 750 bps.","FY2024 rev guidance lowered to $659-$671M (organic -1% to +1%); non-GAAP EPS raised to $0.27-$0.37.","Repurchased 1.2M shares for $73.9M in Q2; $1.025B used of $1.5B authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007348","json":"https://secwatch.observer/filing/0001558370-24-007348.json","markdown":"https://secwatch.observer/filing/0001558370-24-007348.md","text":"https://secwatch.observer/filing/0001558370-24-007348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/933974/000155837024007348/0001558370-24-007348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/933974/000155837024007348/azta-20240508x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T15:13:32.017569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5e1dbd5d1df23a0df49c7f6ac94f5de6f6aec57","claim":"Azenta, Inc. reported the fiscal quarter ended March 31, 2024 results: revenue $159 million, net income $ (2.47) diluted EPS from continuing operations, EPS $ (2.47) diluted EPS from continuing operations. Guidance lowered.","evidence_excerpt":"Day in March, we are confident in our position and the market opportunity which we are uniquely positioned to capture.” ​ Second Quarter Fiscal 2024 Results ● Revenue was $159 million, up 7% year over year. Organic revenue, which excludes the impacts from foreign exchange, was also up 7% year over year, with a nominal benefit from foreign exchange tailwinds.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/933974/000155837024007348/0001558370-24-007348-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2024"},{"label":"Revenue","value":"$159 million"},{"label":"Net income","value":"$ (2.47) diluted EPS from continuing operations"},{"label":"EPS","value":"$ (2.47) diluted EPS from continuing operations"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}